ADMA News and Press, ADMA Biologics Inc From 02/11/20

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients ...

After announcing it had priced an up-sized secondary offering of its shares at $3.50 per share, ADMA Biologics (NASDAQ: ADMA) shares tumbled 13.5% at 12:15 p.m. EST on Friday. A commercial-stage biotech company , ADMA Biologics markets Bivigam and Asceniv, two plasma-derived, polyclonal, i...

ADMA Biologics (NASDAQ: ADMA ) has priced its public offering of 23.5M common shares at $3.50 per share. Underwriters' over-allotment is an additional ~3.5M shares. Closing date is February 11. More news on: ADMA Biologics, Inc., Healthcare stocks news, Stocks on the move, , Read mor...

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bio...

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bio...

Today, we will study why ADMA Biologics ( ADMA ) is a promising biotech player in 2020. Company overview ADMA Biologics is a vertically-integrated biopharmaceutical company focused on developing and commercializing plasma-based therapeutics for the immunocompromised patient population. ...

ADMA Biologics ( ADMA ) recently publicized their preliminary unaudited Q4 and 2019 revenues of $11.9M and $29.2M, respectively. Furthermore, ADMA was nice enough to provide updates on the launches of BIVIGAM and ASCENIV. The market reacted positively to the news with the stock rising from a...

Gainers: Trillium Therapeutics (NASDAQ: TRIL ) +106% . More news on: Trillium Therapeutics Inc., Applied Genetic Technologies Corporation, Genetic Technologies Limited, Stocks on the move, Read more ...

Applied Genetic Technologies (NASDAQ: AGTC ) +53%  on positive XLRP data . More news on: Applied Genetic Technologies Corporation, VBI Vaccines Inc., The Peck Company Holdings, Inc., Stocks on the move, Read more ...

ADMA Biologics (NASDAQ: ADMA ) is up  10%  premarket on announcing preliminary Q4 and FY 2019 revenues, providing updates on the commercial launches of BIVIGAM and ASCENIV, as well as introducing 2020 strategic outlook. More news on: ADMA Biologics, Inc., Healthcare stocks news...